GLP-1semaglutidehfpefglp-1preclinical

Semaglutide cuts LVEDP 60% in rat HFpEF without weight loss

Benefits held in Göttingen minipigs, where delayed dosing normalized wedge pressure and reversed hepatic bridging fibrosis while body weight was unchanged.

By Maren Holt · Senior Reporter, GLP-1

Oct 4 20:00 ETSource: European heart journal

The wire

01In European Heart Journal, semaglutide at doses chosen not to induce weight loss lowered left ventricular end-diastolic pressure about 60% and cut cardiac hypertrophy roughly 30% in ZSF1 Obese rats.
02Suggests incretin cardiac effects in HFpEF may run partly through non-weight-loss pathways, relevant to clinicians weighing semaglutide in patients with limited weight response.
03Findings are preclinical, with 12 rats per group and four to five minipigs per arm; authors say dose equivalence to human regimens still needs defining.

From the source

Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction
European heart journal · 2026 Oct 5 · Elbatreek MH, Li Z, Yu X et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42830666/